REFERENCES

1. Greene-Schloesser D, Moore E, Robbins ME. Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res 2013;19:2294-300.

2. Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008;72:1311-8.

3. Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol 2017;13:52-64.

4. Pereira Dias G, Hollywood R, Bevilaqua MC, da Luz AC, Hindges R, et al. Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms. Neuro Oncol 2014;16:476-92.

5. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med 2002;8:955-62.

6. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013;15:1429-37.

7. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003;9:275-308.

8. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.

9. Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychiatry 2013;74:810-6.

10. Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, et al. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 2004;22:4795-803.

11. Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol 2015;33:1653-9.

12. Levels of evidence. BJU Int 2011;107:870.

13. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCI in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007;69:1496-501.

14. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16:2522-7.

15. Shaw EG, Rosdhal R, D’Agostino RB Jr, Lovato J, Naughton MJ, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006;24:1415-20.

16. Correa DD, Kryza-Lacombe M, Baser RE, Beal K, DeAngelis LM. Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol 2016;127:313-9.

17. Castellino SM, Tooze JA, Flowers L, Hill DF, McMullen KP, et al. Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study. Pediatr Blood Cancer 2012;59:540-7.

18. Jatoi A, Kahanic SP, Frytak S, Schaefer P, Foote RL, et al. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 2005;13:66-9.

19. Attia A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol 2014;15:539-50.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/